Safety and Efficacy of Rituximab and Cyclophosphamide in a Case of Resistant Acquired Hemophilia A in Course of Chronic Lymphocytic Leukemia

Acquired Hemophilia A (AHA) is a rare disease caused by anti-factor VIII autoantibodies. It is usually characterized by clinically significant bleeding at the onset and requires prompt hemostatic and immunosuppressive therapies. Due to its rarity and the lack of randomized trials, its treatment is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazziotta, Francesco, Cecconi, Nadia, Iovino, Lorenzo, Cervetti, Giulia, Petrini, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2019
Materias:
Allergy/Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822901/
https://www.ncbi.nlm.nih.gov/pubmed/31700733
http://dx.doi.org/10.7759/cureus.5630
Descripción
Sumario:Acquired Hemophilia A (AHA) is a rare disease caused by anti-factor VIII autoantibodies. It is usually characterized by clinically significant bleeding at the onset and requires prompt hemostatic and immunosuppressive therapies. Due to its rarity and the lack of randomized trials, its treatment is a great challenge, especially in the relapse/refractory setting. This report presents the case of a patient diagnosed with chronic lymphocytic leukemia who developed a steroid-resistant AHA, successfully managed with aggressive immunosuppressive therapy.

Ejemplares similares